Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

BUY
$171.37 - $283.23 $3.19 Million - $5.27 Million
18,600 New
18,600 $4.97 Million
Q3 2023

Nov 14, 2023

SELL
$146.04 - $225.78 $5.08 Million - $7.86 Million
-34,800 Reduced 58.0%
25,200 $3.68 Million
Q2 2023

Aug 14, 2023

BUY
$203.88 - $312.0 $12.2 Million - $18.7 Million
60,000 New
60,000 $13.9 Million
Q4 2022

Feb 14, 2023

BUY
$58.39 - $296.54 $1.37 Million - $6.94 Million
23,400 Added 93.6%
48,400 $14 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $757,125 - $993,875
12,500 Added 100.0%
25,000 $1.63 Million
Q2 2022

Aug 15, 2022

SELL
$58.04 - $100.2 $725,500 - $1.25 Million
-12,500 Reduced 50.0%
12,500 $895,000
Q1 2022

May 13, 2022

BUY
$55.89 - $101.89 $1.4 Million - $2.55 Million
25,000 New
25,000 $2.45 Million
Q1 2021

May 17, 2021

SELL
$108.54 - $125.2 $1.09 Million - $1.25 Million
-10,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$99.78 - $124.21 $997,800 - $1.24 Million
10,000 New
10,000 $1.19 Million
Q3 2019

Nov 14, 2019

SELL
$84.4 - $106.53 $5.48 Million - $6.91 Million
-64,900 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$91.13 - $142.5 $3.27 Million - $5.12 Million
-35,900 Reduced 35.62%
64,900 $6.8 Million
Q4 2018

Jan 30, 2019

BUY
$94.77 - $215.54 $9.55 Million - $21.7 Million
100,800 New
100,800 $11.4 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.34B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Caption Management, LLC Portfolio

Follow Caption Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.